SEC Form 4Coverage since May 21, 2026
$RNTX insider trading
Over the last 12 months, Rein Therapeutics insiders reported 1 buy totaling $50K and no sales across SEC Form 4 filings.
- Bought · 12m
- $50K 1 event
- Sold · 12m
- — 0 events
- Events · 12m
- 1 Form 4 filings, grouped
- Insiders · 12m
- 1 distinct reporters
- 10b5-1 share
- 0% pre-arranged plans
Side
Price · $RNTX · 12Mvia TradingView
Top insiders · 12m
VON RICKENBACH JOSEF H—1× · $50K
All insider trades
1 event
| Date | Insider | Type | Shares | Avg price | Value | Δ stake | Marks |
|---|---|---|---|---|---|---|---|
| May 27, 2026 | VON RICKENBACH JOSEF HD | ▲ Buy | 47,060 | $1.05 | $50K | +304.5% | 4 tranches |
About Form 4
Corporate insiders — officers, directors and 10%+ owners — must report their trades to the SEC on Form 4 within two business days. We group each filing's transactions into one economic event (a laddered 10b5-1 sale is one event, not 25 rows), flag pre-arranged plans and late filings, and link every event to its AI-scored article in the $RNTX feed.